Brown & Brown, Inc. (NYSE:BRO) is demonstrating a robust performance in the bio-tech market. Among its impressive feats includes becoming one of Lountzis Asset Management LLC's largest positions. Investors have reportedly seen a solid return of 164% over the last five years. Share movement has been dynamic, with DekaBank Deutsche Girozentrale selling 8,508 shares, while Penserra Capital Management, Silver Oak Securities, and others acquired respective stakes. The firm has recently signed a nearly $10 billion deal with rival broker Accession and facilitated a $4 billion stock offering to fund strategic acquisitions. As per some brokerage's price target, BRO's shares are expected to reach an average price of $118.85. The firm is not underperforming in the financial services sector. There have been concerns over insiders selling stock alluding to potential weakness, but, overall, the company maintains a positive public perception. They have also announced a 15% increase in their quarterly cash dividend. The company remains hopeful despite higher expenses reflected in Q1 earnings.
Brown Brown BRO News Analytics from Wed, 23 Oct 2024 07:00:00 GMT to Sat, 12 Jul 2025 22:02:09 GMT -
Rating 7
- Innovation 4
- Information 8
- Rumor -2
